Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Bel (Amsterdam, Netherlands), W. Moore (Winston-Salem, NC, United States of America), O. Kornmann (Frankfurt, Germany), C. Poirier (Montreal, QC, Canada), N. Kaneko (Kamogawa, Japan), S. Smith (Research Triangle Park, NC, United States of America), N. Martin (Brentford, Middlesex and Leicester, United Kingdom), M. Gilson (Uxbridge, Middlesex, United Kingdom), R. Price (Stevenage, Hertfordshire, United Kingdom), E. Bradford (Research Triangle Park, NC, United States of America), M. Humbert (Paris, France). Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. 5280

Member's Comments

No comment yet.

Related content which might interest you: Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021 Year: 2022 Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Severe asthma exacerbations with eosinophilic bronchitis: a randomized controlled comparison of the anti-inflammatory effects of deflazacort vs. prednisone Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Early treatment response may predict long-term mepolizumab benefit in severe asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Severe asthma outcomes over two years of therapy with mepolizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015